Ondansetron is indicated for Management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention of post-operative nausea and vomiting in adults. Ondansetron is a molecule in the family of the 5-HT3 receptor antagonists and is the leading anti-emetic molecule in both CINV (Chemotherapy Induced Nausea and Vomiting and PONV (Post Operatiev Nausea and Vomiting). Ondasetron sold USD 933 Million in 2008 in the major 7 markets, 48% of the total USD 1.9 Billions anti-emetic market .

APR developed the proprietary RapidFilm™ technology which is a novel, non-mucoadhesive, fast dissolving oral dosage form based on a water soluble polymer. Placed on top of the tongue, the film disperses within seconds (water is not needed), promoting a gastrointestinal absorption comparable to immediate release oral solid dosage forms.

The Ondansetron RapidFilm® was especially designed for higher patient compliance. Considering that the target population suffer of nausea and vomiting, Ondansetron RapidFilm® offers multiple competitive advantages versus the already marketed pharmaceutical forms of Ondansetron: easier dosing accuracy, easy to be handled, stored and taken away, no need water.